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Abstract
Mechanisms of long term action of antiepileptic drugs (AEDs), used in treating epilepsy 
and many other neurological and psychiatric disorders, are poorly understood. Recently, 
a  novel  Drosophila transcriptomic  model  of  locomotor  plasticity  induced by  chronic 
pentylenetetrazole (PTZ), a chemoconvulsant commonly used to model epileptogenesis 
and test AEDs in rodents, has been described. In this model, two of the five AEDs tested, 
sodium valproate (NaVP) and levetiracetam (LEV), not ethosuximide (ETH), gabapentin 
(GBP) and vigabatrin (VGB), ameliorate development of chronic PTZ induced locomotor 
alteration. Here, we describe transcriptomic effect of the AEDs in the fly model. Singular 
treatment  with  ETH,  GBP and  VGB in  general  caused  downregulation  of  genes.  In 
contrast,  similar  treatment  with  NaVP  and  LEV caused  upregulation.  The  GBP and 
NaVP gene sets showed enrichment of the ribosomal and energy metabolic pathways. 
The  network  partners  of  ETH,  VGB  and  LEV  regulated  genes  in  the  available 
interactome map were also found to overrepresent the ribosomal pathway. Unlike PTZ 
alone, PTZ and LEV combination treatment was found to cause differential regulation of 
genes that too enriched the ribosomal and energy metabolic pathways. Cumulatively, we 
provide  transcriptomic  evidence  that  suggests  involvement  of  ribosomal  and  energy 
metabolic  mechanisms  in  AED action.  The  Drosophila model  provides  an  excellent 
opportunity to further understand mechanisms of AED action in molecular details.
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Introduction
AEDs  are  used  in  treating  various  neurological  and  psychiatric  conditions  besides 
epilepsy (1, 2, 3). Overlapping pathophysiological mechanisms are considered to underlie 
epilepsy and other nonepileptic conditions (1, 4). Though immediate biochemical effects 
of AEDs are known to some extent, the mechanisms underlying longer term therapeutic 
action  of  these  drugs  are  poorly  understood  (2,  5,  6,  7).  Kindling  in  rodents  is  an 
established model of epileptogenesis (8, 9) - process whereby structural and functional 
changes occur following a brain insult that in some cases result in epilepsy and, in some 
epilepsies, progress to cause abnormalities such as emotional and cognitive deficits - and 
AED testing (10, 11, 12, 13, 14). Kindling-like phenomena is thus considered relevant in 
various neuropsychiatric conditions (15, 16, 17). Rodent kindling induced by PTZ is a 
commonly used model of drug testing (18). Recently, a  Drosophila systems model of 
pentylenetetrazole  induced  locomotor  plasticity  that  is  responsive  to  AEDs has  been 
described (19). In this model, seven days of PTZ treatment and seven days of subsequent 
PTZ discontinuation respectively cause a decrease and an increase in climbing speed of 
adult Drosophila males. Concomitant treatment with two of five AEDs tested, NaVP and 
LEV, not ETH, GBP and VGB, suppress the development of locomotor deficit at the end 
of chronic PTZ phase (19). Concomitant LEV also ameliorates locomotor alteration that 
develops after PTZ withdrawal. Time series of microarray expression profiles of heads of 
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flies  treated  with PTZ has revealed downregulation of  genes enriched  in several  GO 
biological processes such as transcription, neurogenesis, glutamate metabolism etc. (19). 
Enrichment of Wnt signaling and other associated pathways has also been observed in the 
set of genes downregulated by PTZ. The  Drosophila gene expression model has been 
found to be consistent with transcriptomic and proteomic data pertaining to established 
rodent models of epilepsy and human epileptic patients (19). Availability of the fly model 
thus offers a unique opportunity to understand mechanisms of long term action of AEDs 
at systems level. Here, we present transcriptomic effect of AEDs in the fly model.
Results
Transcriptomic effect of AEDs
Microarray gene expression profiles of fly heads were generated after treating the animal 
for  three  days  with  ETH,  GBP,  VGB,  NaVP  or  LEV mixed  in  normal  food  (NF). 
Clustering of the profiles revealed two major groups, one consisting of ETH, GBP and 
VGB,  and  the  other  NaVP  and  LEV  (Fig.  1).  The  result  was  consistent  with  the 
previously reported  behavioral  pharmacology of fly model  in which the former  three 
drugs  were  found to  be  ineffective  whereas  the  latter  two ameliorated  PTZ induced 
development of locomotor abnormality (19). Next, we identified differentially expressed 
genes  in  the  AED  associated  profiles.  Each  of  the  five  AEDs  caused  differential 
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expression of genes (Table S1, supporting material). Whereas ETH caused both up- 
and down-regulation, GBP and VGB caused only down, and NaVP and LEV only up. 
The RT-PCR validated majority of randomly selected differentially expressed genes in 
microarrays  (Fig.  2).  We  next  examined  gene  ontology  (GO)  biological  process 
enrichment in genes regulated by AEDs. The AEDs except VGB were found to regulate 
genes that enriched one or more processes (Table 1). Enrichment of calcium-mediated 
signaling  in  genes  regulated  by  ETH,  a  Ca++ channel  blocker,  and  of  glutamate 
metabolism in genes regulated by GBP, a drug with GABAergic effect, was notable.  In 
order to further comprehend the transcriptomic data, we examined if the AED regulated 
genes enrich biochemical pathway(s). Interestingly,  genes downregulated by GBP and 
upregulated  by  NaVP  were  found  to  overrepresent  ribosomal  pathway  (Fig.  3). 
Correcting for multiple statistical testing may be overly conservative to the point of being 
counterproductive  in  interpreting  microarrays  with  biological  knowledgebases  (20). 
Given this, it was notable that pathways showing enrichment in genes downregulated by 
GBP and upregulated by NaVP at nominal p values included energy metabolic pathways 
(Table  2).  These  pathways  included  pyruvate  metabolism,  TCA  cycle, 
glycolysis/gluconeogenesis and oxidative phosphorylation. The first one was common in 
GBP and NaVP sets (Fig. 4). To examine the possibility that the rest of the AEDs may 
also  affect  ribosomal  and/or  energy  metabolic  pathways,  an  indirect  approach  was 
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adopted. We retrieved the interacting partners of ETH, VGB and LEV associated genes, 
and  their  interactors,  and  so  on,  in  the  available  protein  interactome  network. 
Remarkably,  ETH,  VGB  and  LEV  sub-networks  showed  enrichment  of  ribosomal 
pathway within one (p = 0.016), two (p = 4.35E-10) and three rounds (p = 7.04E-14) of 
interactions,  in  that  order.  Cumulatively,  direct  or  indirect  evidence  of  ribosomal 
pathway enrichment was obtained for genes downregulated by ETH, GBP and VGB, and 
upregulated by LEV and NaVP.
Transcriptomic effect of LEV and PTZ combined
A centrally active drug may act differently under normal and pathological conditions. To 
examine if ribosomal mechanism of AEDs is causally involved in the fly PTZ model, we 
used  LEV as  an  example.  In  the  behavioral  model,  LEV  has  earlier  been  found  to 
ameliorate PTZ induced development of locomotor deficit (19). The time series analysis 
of PTZ induced transcriptomic alterations has earlier shown that PTZ causes down-, not 
up-, regulation of genes (19).  In contrast, the present analysis showed that LEV causes 
only upregulation. We argued that if ribosomal pathway is causally involved in LEV’s 
mechanism of  action  then  PTZ and  LEV combined treatment  may possibly  regulate 
genes enriched in ribosomal pathway. We tested this hypothesis by generating microarray 
expression  profiles  of  fly  heads  after  treating  the  animals  with  both  PTZ and  LEV 
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together for 12 h and 2 d. We first clustered these newly generated expression profiles 
with previously described 12 h and 2 d PTZ alone profiles (19). The cluster showed 12 h 
time point of the PTZ and LEV combined treatment as most distinct from rest of the three 
profiles (Fig. 5). We next identified differentially expressed genes in the combination 
treatment.  Only up- and only down-regulated genes were found at 12 h and 2 d time 
points, in that order (Table S2, supporting material). The differentially expressed gene 
sets showed enrichment  for various biological processes (Table 3).  Remarkably,  both 
gene sets, irrespective of direction of regulation, were found to enrich ribosomal pathway 
(Fig. 6). Interestingly, these sets were also found to enrich energy metabolic pathways at 
unadjusted  p values  (Table  4).  Whereas  12  h  upregulated  genes  enriched  pyruvate 
metabolism  (Fig.  7)  and  TCA  cycle,  the  2  d  downregulated  genes  enriched 
glycolysis/gluconeogenesis and oxidative phosphorylation. To compare with the 12 h and 
2 d PTZ alone genes described earlier (19), we examined pathway enrichment therein. 
The  former  time  point  was  not  enriched  for  any  pathway.  However,  enrichment  of 
glycolysis/gluconeogenesis was observed for downregulated genes in the latter time point 
(unadjusted  p = 0.026). Cumulatively,  the above results  demonstrated involvement of 
ribosomal pathway in the mechanism of action of LEV. Both up- and down-regulation of 
the pathway was found to be involved in the long-term action. The above results also 
supported  the  evidence  that  genes  in  ribosomal  and  energy  metabolic  pathways  are 
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coregulated.
Discussion
Transcriptomic effect of AEDs shows consistency with known aspects of the drugs
Microarray clustering showed consistency with known aspects of AEDs. For example, 
ETH is specifically used in the treatment of absence seizure (21) and the cluster shows 
this AED as a distinct drug. GBP and VGB are known not to show much impact on the 
prognosis of patients with intractable epilepsy (22) and the cluster groups the two drugs 
together. Evidence of efficacy exists for NaVP and LEV in treating status epilepticus (23) 
and the cluster shows them in one group.  The clustering is also consistent with known 
aspects  of  drugs’  biochemical  effects.  For  example,  it  is  consistent  with T-type Ca++ 
channel blocker activity of ETH (24), GABAergic effect of GBP and VGB (25), and both 
GABAergic and Ca++ channel mechanisms of NaVP and LEV (26, 27, 28).
Evidence suggests involvement of ribosomal mechanisms in AEDs’ action
All  the  five  AEDs  used  caused  differential  expression  of  genes  which  directly  or 
indirectly through interacting genes overrepresented ribosomal pathway. The evidence 
has  been  direct  for  GBP  and  NaVP,  and  indirect  for  ETH,  VGB  and  LEV. 
Transcriptomic evidence suggested that ETH, GBP and VGB downregulate,  and LEV 
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and NaVP upregulate  ribosomal pathway. Comparison  of PTZ and LEV combination 
with  PTZ alone  treatment  revealed  involvement  of  both  up-  and  down-regulation  of 
ribosomal pathway in the mechanism of AED action. Irrespective of directional change, 
unequivocal evidence for a central role of ribosomal pathway in AEDs’ mechanisms has 
been  obtained.  Emerging  evidence  implicates  ribosomal  proteins  as  novel  epigenetic 
regulators of gene transcription, from  Drosophila to mammals (29, 30, 31). Epigenetic 
modifications  are  increasingly  being  recognized  as  major  and  critical  factors  in  the 
regulation of gene expression. These modifications have been implicated in a variety of 
brain conditions including neurological and psychiatric disorders (32, 33, 34, 35, 36). 
Given  the wide use of  AEDs in  various  neurological  and psychiatric  conditions,  our 
results revealing regulation of ribosomal protein encoding genes by a variety of AEDs 
may tempt us to speculate that the latter act through epigenetic mechanisms mediated by 
ribosomal pathway. It is notable here that already NaVP is a known epigenetic drug (37). 
Epigenetic regulation of gene expression in the brain is a relatively new area of research 
(33).  Our  Drosophila model  may  provide  an  excellent  opportunity  to  understand 
epigenetic mechanisms in CNS disorders and drug action in molecular details.
Ribosomal and energy metabolic pathways exhibit coregulation
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Singular treatment of GBP and NaVP, and the combination treatment of PTZ and LEV 
together caused differential expression of genes that, in the same direction of expression 
change, overrepresented both ribosomal and energy metabolic pathways. This suggested 
that the two pathways are coregulated. A link between energy metabolism and epigenetic 
mechanisms  involving  histone  modifications  is  known  to  exist  (38,  39).  Also, 
antiepileptic as well as psychotic and antipsychotic mechanisms are known to involve 
energy metabolism (9, 40, 41, 42, 43, 44, 45). Further, energy impairment is considered 
as a mechanism underlying pathophysiology of epilepsy as well as a variety of other 
neuropsychiatric  disorders  (46,  47,  48).  Evidence  suggests  conserved  mechanisms 
between Drosophila bang-sensitive mutants and human seizure disorders (49). Molecular 
defects in five such mutants involve genes encoding mitochondrial  ribosomal protein, 
ADP/ATP  translocase,  the  citrate  synthase,  an  ethanolamine  kinase,  and  an 
aminopeptidase.  Prevalence  of  mitochondrial  function  disrupting  defects  in  bang-
sensitive mutants suggests that impaired energy metabolism may underlie the affected 
behavior in  Drosophila (49). Importantly, human seizure disorders have been linked to 
mutations in genes encoding pyruvate carboxylase, and pyruvate dehydrogenase, the two 
enzymes upstream of citrate synthase, as well as to mutations affecting various steps in 
the TCA cycle (49). Given this, our hypothesis that AEDs may act through epigenetic 
mechanisms mediated by ribosomal proteins is consistent with the finding of ribosomal 
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and metabolic pathway coregulation. It is tempting to speculate a unifying mechanism for 
neuropsychiatric  conditions  and  centrally  acting  drugs,  wherein  neurometabolic 
dysfunction alters epigenetic codes in the brain via regulating expression of ribosomal 
components.
The ultimate aim of systems biology is to delineate and comprehend the functioning of 
complex biological  systems in  such details  that  predictive  models  of  human diseases 
could be developed. Similar approach may be adopted to understand the mechanisms of 
action of therapeutic  and pharmacological  tool compounds at  systems level.  Immense 
complexity  of  higher  organisms  precludes  them  from  being  efficiently  used  for 
developing systems level understanding. In this context, it assumes significance that a 
Drosophila systems model of pentylenetetrazole induced locomotor plasticity responsive 
to  AEDs has  recently  been developed.  The value of  this  model  is  apparent  from the 
present unraveling of a novel aspect of AED mechanisms. Amenability of Drosophila for 
systems level modeling allowed us to identify involvement of ribosomal mechanisms in 
the action of a wide variety of AEDs. We also observed coregulation of ribosomal and 
energy  metabolic  processes.  Converging  evidence  allowed  us  to  propose  a  unifying 
hypothesis to explain pathophysiology of neuropsychiatric disorders and drugs used in 
treating  such  disorders.  We  have  proposed  here  that  disease  and  drug  mechanisms 
involve  neurometabolic  dysfunction  that  alters  epigenetic  codes  in  the  brain  via 
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regulating  ribosomal  constituents.  The  fly  model  potentially  offers  an  excellent 
opportunity to examine the possible epigenetic aspects of brain function. Besides, the 
model also provides a simple screen for identifying novel therapeutic compounds. For 
example,  molecules  causing  gene  expression  alterations  similar  to  NaVP or  LEV in 
Drosophila may  be  labeled  as  potential  lead  molecules  for  further  investigation. 
Similarly, pharmacogenomic candidates can be identified using the model. In brief, the 
fly systems model holds both basic as well as applied value.
Materials and Methods
Flies and drug treatment
Unless mentioned otherwise, previously described materials and methods were used (19). 
In brief, standard fly medium consisting of agar-agar, maize powder, brown sugar, dried 
yeast and nipagin was used. Standard methods of fly handling and manipulation were 
followed. Ten to eleven days old unmated males were used to begin three day long AED 
treatment. Three to four days old flies were used to begin PTZ and LEV concomitant 
treatment for 12 h. Final concentration of PTZ, ETH, NaVP, GBP, VGB (all from Sigma-
Aldrich) and LEV (Levesam 500, Nicholas Piramal) in NF was 8, 3.48, 0.33, 16, 24 and 
5 mg/ml, in that order.
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Microarrays
Previously described method was used (19). In brief, total RNA was isolated from frozen 
fly  heads  using  TRI  REAGENT  (Sigma),  according  to  the  manufacturer’s  protocol. 
Microarray -cDNA Synthesis Kit, -Target Purification Kit, and -RNA Target Synthesis 
Kit (Roche) were used to generate  labeled antisense RNA. Four  biological replicates, 
with balanced dye-swap, were used for generating expression profiles. The hybridization 
mixture  was  denatured  at  65ºC  and  applied  onto  cDNA  microarray  slides  (12Kv1, 
CDMC,  Canada).  Analyzable  spots  in  at  least  three  of  four  biological  replicates 
performed  were  retrieved  for  downstream  analysis  using  significant  analysis  of 
microarrays (SAM 3.0, Excel Add-In) (50), under the conditions of one class response 
and 100 permutations.  Differentially expressed genes in AED associated profiles were 
identified at an average false discovery rate (FDR) of 20% (range 16-25%). Our selection 
of FDR was based on a compromise between uniformity across time points in terms of 
number of differentially expressed genes and acceptability in terms of incorporating false 
positives. All microarray data reported in the manuscript is described in accordance with 
MIAME  guidelines.  The  full  microarray  data  set  has  been  deposited  in  the  Gene 
Expression  Omnibus  (http://www.ncbi.nlm.nih.gov/geo/)  under  accession  series 
GSE7199,  GSE7202,  GSE7203,  GSE7200,  GSE7488  and GSE10850.  Previously,  a 
control microarray experiment in which heads of four biological replicates of NF treated 
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flies were compared using the same procedure used here (19). No differentially expressed 
gene was found in this NF versus NF microarrays in SAM analysis up to 96% FDR. The 
present 20% FDR cut-off was thus considered reasonable.
Real-Time quantitative PCR
Previously described method was used (19).  In brief,  RT-PCR amplification reactions 
were carried out in an ABI Prism 7700 sequence detection system (Applied Biosystems, 
LabIndia facility,  Gurgaon).  All  genes were  detectable under  the detection thresholds 
(CT<36) recommended by Applied Biosystems (51). ABI gene expression assay IDs used 
were  as  follows:  Men,  Dm02148936_m1;  Cyp28d1,  Dm01804635_g1;  RfaBp, 
Dm01825573_m1;  Gapdh1,  Dm01843827_s1;  ScP1,  Dm03420546_m1;  Kr, 
Dm01821853_g1;  Got2,  Dm01846045_m1;  CG6409,  Dm02367441_s1;  wupA, 
Dm01828736_m1;  Pdk,  Dm01842786_m1;  exd,  Dm01813679_g1;  CG9238, 
Dm01805173_m1; CG9485, Dm01817100_m1.
Bioinformatics
Gene  symbols  or  Flybase  IDs  corresponding  to  substances  on  the  microarrays  were 
retrieved  using  FLIGHT  (http://www.flight.licr.org/).  GOTool  Box 
(http://burgundy.cmmt.ubc.ca/GOToolBox/)  (52)  was  used  to  retrieve  overrepresented 
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GO biological processes in differentially regulated genes, after Bonferroni adjustment for 
multiple testing. Unless mentioned otherwise, pathway enrichment was analyzed using 
DAVID (http://david.abcc.ncifcrf.gov/home.jsp) with Benjamini adjustment for multiple 
testing  (53). The  protein  interactome  database  BioGRID  v  2.0 
(http://www.thebiogrid.org/index.php) (54)  was  used  in  conjunction  with  the 
visualization  software  Osprey  v.  1.2.0  (http://biodata.mshri.on.ca/osprey/servlet/Index) 
for  retrieving  interaction  networks.  KEGG 
(http://www.genome.jp/kegg/tool/color_pathway.html)  was used for  depicting genes in 
the pathways.
References
1. Rogawski MA, Loscher W (2004) The neurobiology of antiepileptic drugs for the 
treatment of nonepileptic conditions. Nat Med 10: 685-692.
2. Johannessen  LC  (2008)  Antiepileptic  drugs  in  non-epilepsy  disorders:  relations 
between mechanisms of action and clinical efficacy. CNS Drugs 22: 27-47.
3. Grunze  HC (2008)  The  effectiveness  of  anticonvulsants  in  psychiatric  disorders. 
Dialogues Clin Neurosci 10: 77-89.
4. Adams SJ, O’Brien TJ, Lloyd J, Kilpatrick CJ, Salzberg MR, Velakoulis D (2008) 
Neuropsychiatric morbidity in focal epilepsy. Br J Psychiatry 192: 464-469.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
5. Rosenberg  G  (2007)  The  mechanisms  of  action  of  valproate  in  neuropsychiatric 
disorders: can we see the forest for the trees? Cell Mol Life Sci 64: 2090-2103.
6. Nagarkatti  N,  Deshpande  LS,  DeLorenzo  RJ  (2008)  Levetiracetam  inhibits  both 
ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal 
neurons in culture. Neurosci Lett 436: 289-293.
7. Kuzniecky R, Pan J, Burns A, Devinsky O, Hetherington H (2008) Levetiracetam has 
no acute effects on brain gamma-aminobutyric acid levels. Epilepsy Behav 12: 242-
244.
8. McNamara  JO,  Huang  YZ,  Leonard  AS (2006)  Molecular  signaling  mechanisms 
underlying epileptogenesis. Sci STKE 356, p. re12.
9. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ et  al.  (2006) 2-
Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic 
regulation of chromatin structure. Nat Neurosci 9: 1382-1387.
10. Walker MC, White HS, Sander JW (2002) Disease modification in partial epilepsy. 
Brain 125: 1937-1950.
11. Husum H,  Bolwig TG,  Sanchez  C,  Mathe  AA,  Hansen  SL (2004)  Levetiracetam 
prevents changes in levels of brain derived neurotrophic factor and neuropeptide Y 
mRNA  and  Y1-  and  Y5-like  receptors  in  the  hippocampus  of  rats  undergoing 
amygdale  kindling:  implications  for  antiepileptogenic  and  mood-stabilizing 
properties. Epilepsy Behav 5: 204-215.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
12. Jia  F,  Kato  M,  Dai  H,  Xu  A,  Okuda  T  et  al.  (2006)  Effects  of  histamine  H(3) 
antagonists and donepexil on learning and mnemonic deficits induced in weanling 
mice. Neuropharmacology 50: 404-411.
13. Pavlova T, Stepanichev M, Gulyaeva N (2006) Pentylenetetrazole kindling induces 
neuronal cyclin B1 expression in rat hippocampus. Neurosci Lett 392: 154-158.
14. De Smedt T, De Rouck S, Raedt R, Wyckhuys T, Waterschoot L et al. (2007) Serial 
day rapid kindling is an effective tool in screening the anti-epileptic properties of 
topiramate. Seizure 16: 620-626.
15. Becker A, Schmitz M, Grecksch G (2006) Kindling modifies morphine, cocaine and 
ethanol place preference. Exp Brain Res 168: 33-40.
16. Mortazavi  F,  Ericson M, Story D, Hulce VD, Dunbar  GL (2005) Spatial  learning 
deficits  and  emotional  impairements  in  pentylenetetrazole-kindled  rats.  Epilepsy 
Behav 7: 629-638.
17. Bob P,  Glaslova K, Susta  M, Jasova D, Raboch J  (2006)  Traumatic  dissociation, 
epileptic-like phenomena, and schizophrenia. Neuro Endocrinol Lett 27: 321-326.
18. de Oliveira PA, Lino FL, Cappelari SE, da Silva Brum LF, Picada JN et al. (2008) 
Effects of gamma-decanolactone on seizures induced by PTZ-kindling in mice.  Exp 
Brain Res 187: 161-166.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
19. Mohammad  F,  Singh  P,  Sharma  A  (2009)  A  Drosophila  systems  model  of 
pentylenetetrazole  induced  locomotor  plasticity  responsive  to  antiepileptic  drugs. 
BMC Syst Biol 3: 11.
20. Osier MV, Zhao H, Cheung KH (2004) Handling multiple testing while interpreting 
microarrays with the Gene Ontology Database. BMC Bioinformatics 5: 124.
21. Gören MZ, Onat F (2007) Ethosuximide: from bench to bedside. CNS Drug Rev 13: 
224-239.
22. Cruczwar SJ, Patsalos PN (2001) The new generation of GABA enhancers. Potential 
in the treatment of epilepsy. CNS Drugs 15: 339-350.
23. Selvitelli M, Drislane FW (2007) Recent developments in the diagnosis and treatment 
of status epilepticus. Curr Neurol Neurosci Rep 7: 529-535.
24. Cheng  JK,  Lin  CS,  Chen CC,  Yang JR,  Chiou  LC (2007)  Effects  of  intrathecal 
injection  of  T-type  calcium  channel  blockers  in  the  rat  formalin  test.  Behav 
Pharmacol 18: 1-8.
25. Pereira  MB,  Freitas  RL,  Assis  MA,  Silva  RF,  Fonteles  MM et  al.  (2007)  Study 
pharmacologic  of  the GABAergic  and glutamatergic  drugs  on seizures  and status 
epilepticus induced by pilocarpine in adult Wistar rats. Neurosci Lett 419: 253-257.
26. Broicher T, Seidenbecher T, Meuth P, Munsch T, Meuth SG et al. (2007) T-current 
related effects of antiepileptic drugs and a Ca2+ channel antagonist on thalamic relay 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
and local circuit interneurons in a rat model of absence epilepsy. Neuropharmacology 
53: 431-446.
27. Sankar  R,  Holmes  GL  (2004)  Mechanisms  of  action  for  the  commonly  used 
antiepileptic  drugs:  relevance  to  antiepileptic  drug-associated  neurobehavioral 
adverse effects. J Child Neurol 19 Suppl 1: S6-14.
28. Gobbi  G,  Janiri  L  (2006)  Sodium-  and  magnesium-valproate  in  vivo  modulate 
glutamatergic  and  GABAergic  synapses  in  the  medial  prefrontal  cortex. 
Psychopharmacology (Berl) 185: 255-262.
29. Brogna S, Sato TA, Rosbash M et al. (2002) Ribosome components are associated 
with sites of transcription. Mol Cell 10: 93-104.
30. Ni JQ, Liu LP, Hess D, Rietdorf J, Sun FL (2006) Drosophila ribosomal proteins are 
associated with linker histone H1 and suppress gene transcription.  Genes Dev 20: 
1959-1973.
31. Lindström  MS (2009)  Emerging  functions  of  ribosomal  proteins  in  gene-specific 
transcription and translation. Biochem Biophys Res Commun 379: 167-170.
32. Deutsch  SI,  Rosse  RB,  Mastropaolo  J,  Long  KD, Gaskins  BL (2008)  Epigenetic 
therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime 
time? Clin Neuropharmacol 31:104-119.
33. Jiang  Y,  Langley  B,  Lubin  FD,  Renthal  W,  Wood MA et  al.  Epigenetics  in  the 
nervous system. J Neurosci 28: 11753-11759.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
34. Peedicayil J (2008) Epigenetic biomarkers in psychiatric disorders. Br J Pharmacol 
155: 795-796.
35. Gräff J, Mansuy IM (2008) Epigenetic codes in cognition and behaviour. Behav Brain 
Res 192: 70-87.
36. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N et al. (2009) HDAC2 
negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
37. Klein C, Kemmel V, Taleb O, Aunis D, Maitre M (2009) Pharmacological doses of 
gamma-hydroxybutyrate  (GHB)  potentiate  histone  acetylation  in  the  rat  brain  by 
histone  deacetylase  inhibition.  Neuropharmacology 
doi:10.1016/j.neuropharm.2009.04.013.
38. Hitchler MJ, Domann FE (2009) Metabolic defects provide a spark for the epigenetic 
switch in cancer. Free Radic Biol Med doi:10.1016/j.freeradbiomed.2009.04.010.
39. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR et al. (2009) ATP-
citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080.
40. Assis LC, Scaini G, Di-Pietro PB, Castro AA, Comim CM et al. (2007) Streck EL, 
Quevedo J: Effect of antipsychotics on creatine kinase activity in rat brain. Basic Clin 
Pharmacol Toxicol 101: 315-319.
41. Bough K (2008) Energy metabolism as part of the anticonvulsant mechanism of the 
ketogenic diet. Epilepsia 49 Suppl 8: 91-93.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
42. Stafstrom  CE,  Roopra  A,  Sutula  TP  (2008)  Seizure  suppression  via  glycolysis 
inhibition with 2-deoxy-D-glucose (2DG). Epilepsia49 Suppl 8: 97-100.
43. Stringer  JL,  Xu K (2008)  Possible  mechanisms for  the  anticonvulsant  activity  of 
fructose-1,6-diphosphate. Epilepsia 49 Suppl 8: 101-103.
44. Garcia  M,  Huppertz  HJ,  Ziyeh  S,  Buechert  M,  Schumacher  M  et  al.  (2009) 
Valproate-induced metabolic changes in patients with epilepsy: assessment with H-
MRS. Epilepsia 50: 486-492.
45. Lehrmann E, Freed WJ (2008) Transcriptional  correlates of human substance use. 
Ann N Y Acad Sci 1139: 34-42.
46. Cloix  JF,  Hévor  T  (2009)  Epilepsy,  regulation  of  brain  energy  metabolism  and 
neurotransmission. Curr Med Chem 16: 841-853.
47. Rezin  GT,  Amboni  G,  Zugno  AI,  Quevedo  J,  Streck  EL  (2009)  Mitochondrial 
dysfunction and psychiatric disorders. Neurochem Res 34: 1021-1029.
48. Ji B, La Y, Gao L, Zhu H, Tian N et al. (2009) A Comparative Proteomics Analysis 
of  Rat  Mitochondria  from the  Cerebral  Cortex  and Hippocampus in  Response  to 
Antipsychotic Medications. J Proteome Res doi: 10.1159/000202823.
49. Fergestad  T,  Bostwick B,  Ganetzky B (2006)  Metabolic  disruption  in  Drosophila 
bang-sensitive seizure mutants. Genetics 173: 1357-1364.
50. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied 
to the ionizing radiation. Proc Natl Acad Sci 98: 5116-5121.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
51. Bookout  AL,  Mangelsdorf  DJ  (2003)  Quantitative  real-time  PCR  protocol  for 
analysis of nuclear receptor signaling pathways. Nucl Recept Signal 1: e012.
52. Martin  D,  Brun  C,  Remy  E,  Mouren  P,  Thieffry  D  et  al.  (2004)  GOToolBox: 
functional investigation of gene datasets based on Gene Ontology. Genome Biol 5: 
R101.
53. Dennis  GJr,  Sherman  BT,  Hosack  DA,  Yang  J,  Gao  W  et  al.  (2003)  DAVID: 
Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: 
P3.
54. Stark C, Breitkreutz B-J, Reguly T, Boucher L, Breitkreutz A et al. (2006) Tyers M. 
BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34: D535-
539.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
39
6.
1 
: P
os
te
d 
3 
Ju
l 2
00
9
Figure legends
Figure 1.
Hierarchical clustering of microarray gene expression profiles associated with treatment 
with AEDs. Note dichotomy between NaVP and LEV as one group and ETH, GBP and 
VGB as another. City Block similarity metric and average linkage methods were used for 
clustering  of  arrays.  Each  AED  profile  represents  mean  of  normalized  log2 ratio 
(635/532)  of  four  biological  replicates  with  balanced  dye-swaps.  The  cluster  was 
generated using Acuity 4.0.
Figure 2.
RT-PCR validation of microarray expression profiles.  A total of 13 genes were randomly 
selected for validation of gene expression changes. Down- and up-regulation of genes 
were all validated except that RT-PCR analysis of  Men,  Cyp28d1,  Got2 and  wupA in 
GBP sample did not confirm their downregulation in microarrays. Absence of AED bar 
indicates that RT-PCR analysis was not determined for that drug.
Figure 3.
Ribosomal  pathway  overrepresentation  in  AED  regulated  genes.  KEGG  pathway 
(http://www.genome.jp/kegg/tool/color_pathway.html)  was  used  to  indicate  down 
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(green)- and up (red)-  regulated genes after  GBP (a) and NaVP (b) treatment, in that 
order. Either gene set significantly enriched the pathway at Benjamini adjusted p values 
(GBP, p = 1.02E-08; NaVP, p = 8.34E-05). Details of pathway enrichment are given in 
Table  2.  Grey  boxes  represent  other  pathway  components  present  in  Drosophila  
melanogaster.
Figure 4.
Pyruvate  metabolism  overrepresentation  in  AED  regulated  genes.  KEGG  pathway 
(http://www.genome.jp/kegg/tool/color_pathway.html)  was  used  to  indicate  down 
(green)- and up (red)-  regulated genes after  GBP (a) and NaVP (b) treatment, in that 
order. Either gene set significantly enriched the pathway at unadjusted p values (GBP, p 
= 0.021; NaVP,  p = 0.012). Details of pathway enrichment are given in Table 2. Grey 
boxes represent other pathway components present in Drosophila melanogaster.
Figure 5.
Hierarchical clustering of microarray gene expression profiles associated with combined 
and  singular  drug  treatment.  Previously  described  (19)  microarrays  of  PTZ  alone 
treatment were clustered along with newly generated profiles of PTZ and LEV combined 
treatment. Note similarity between PTZ alone time points, distinct from PTZ and LEV 
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combined treatment. City Block similarity metric and average linkage methods were used 
for clustering of arrays. Each profile represents mean of normalized log2 ratio (635/532) 
of four biological replicates with balanced dye-swaps. The cluster was generated using 
Acuity 4.0.
Figure 6.
Ribosomal pathway overrepresentation in genes regulated by PTZ and LEV combined 
treatment.  KEGG  pathway  (http://www.genome.jp/kegg/tool/color_pathway.html)  was 
used to indicate up (red)- and down (green)- regulated genes after 12 h (a) and 2 d (b) 
treatment, in that order. Either gene set significantly enriched the pathway at Benjamini 
adjusted p values (12 h, p = 0.02; 2 d, p = 4.13E-18). Details of pathway enrichment are 
given in Table 4. Grey boxes represent other pathway components present in Drosophila  
melanogaster.
Figure 7.
Pyruvate metabolism overrepresentation in genes regulated by PTZ and LEV combined 
treatment.  KEGG  pathway  (http://www.genome.jp/kegg/tool/color_pathway.html)  was 
used to indicate up (red)- regulated genes after 12 h of combination treatment. The gene 
set  significantly enriched  the pathway at  unadjusted  p values (p = 0.038).  Details  of 
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pathway  enrichment  are  given  in  Table  4.  Grey  boxes  represent  other  pathway 
components present in Drosophila melanogaster.
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Figure 1
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Figure 2
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Figure 3
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Figure 4
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Figure 5
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Figure 6
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Figure 7
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